Comparison of efficacy of oral methotrexate and acitretin for generalized lichen planus
DOI:
https://doi.org/10.66344/jpad.v32i2.1890Keywords:
AcitretinAbstract
Objective To compare the efficacy of oral methotrexate and acitretin in the treatment of generalized lichen planus.
Methods The study comprised 36 participants of both sexes who were between the ages of puberty and maturity. It was determined that the efficacy of oral methotrexate 15 mg/week was defined by 50% elimination of mucocutaneous lesions after 12 weeks of treatment. There were four weeks of data collection for nausea and weakness, as well as for haemoglobin (Hb), white blood cell count (WBC), and serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and a safety assessment.
Results The mean age of the patients in Group 1 is 54 years and 52.5years in Group 2, while the mean weight in Group 1 is 71.9 kg and 72.2 kg in Group 2. Methotrexate was shown to be effective with marked improvement in 33.3% and slight improvement in 38.9% of patient. While acitretin showed marked improvement in 33.3% and slight improvement in 33.3% of patients. Patients with mucosal involvement in group 1 were (N=6) and (N=7) in group 2. The overall side effects reported with acitretin group were slightly higher than methotrexate group.
Conclusion In our study, methotrexate and acitretin was proven to be both beneficial and safe for the vast majority of participants.
References
1. Pittelkow MR, Daoud MS. lichen planus. In: Wolff K, Goldsmith LA, Katz SI, editors. Fitzpatrick's Dermatology in General Medicine, 7th ed. McGraw-Hill, New York; 2008: 244-48.
2. Abdallat SA, Maaita TJ. Epidemiological and clinical features of lichen planus in Jordanian patients. Pak J Med Sci. 2007;23:92-4.
3. Perry D, Fazel N. Zosteriform lichen planus. Dermatol Online J. 2006;12:3.
4. Khondker L, Wahab MA, Khan SI. Profile of lichen planus in Bangladesh. Mymensingh Med J. 2010;19:250-3.
5. Crincoli V, Di Bisceglie MB, Scivetti M,Lucchese A, Tecco S, Festa F. Oral lichen planus: update on etiopathogenesis, diagnosis and treatment. Immunopharmacol Immunotoxicol. 2011;33:11-20.
6. Bermejo-Fenoll A, Sanchez-Siles M, López-Jornet P,Camacho-Alonso F, Salazar-Sanchez N. Premalignant nature of oral lichen planus. A retrospective study of 550 oral lichen planus patients from SouthEastern Spain. Oral Oncol. 2009;45:e54-6.
7. Sharma S, Saimbi CS, Koirala B. Erosive oral lichen planus and its management: a case series. J Nepal Med Assoc. 2008;47:86-90.
8. Kalmar JR. Diagnosis and management of oral lichen planus. J Calif Dent Assoc. 2007;35:405-11.
9. Bangert CA, Costner MI. Methotrexate in dermatology. Dermatol Ther. 2007;20:216- 28.
10. Jang N, Fischer G. Case Series. Treatment of erosive vulvovaginal lichen planus with methotrexate. Australas J Dermatol. 2008;49:216-9.
11. Turan H, Baskan EB, Tunali S, Yazici S, Saricaoglu H. Methotrexate for the treatment of generalized lichen planus. J Am Acad Dermatol. 2009;60:164-6.
12. Anbar TE, Barakat M, Ghannam SF. A clinical and epidemiological study of lichen planus among Egyptians of al-Minya province. Dermatol Online J. 2005;11:4.
13. Oliveira Alves MG1, Almeida JD, Balducci I, Guimarães Cabral LA. Oral lichen planus: A retrospective study of 110 Brazilian patients. BMC Res Notes. 2010;3:157.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Ghafoor Ullah, Muhammad Ziaulhaq, Farhad Ali
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
